- Home
- NAOV vs QLGN Comparison
NAOV vs QLGN Comparison
Compare NAOV & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAOV
- QLGN
- Stock Information
- Founded
- NAOV 2003
- QLGN 1996
- Country
- NAOV United States
- QLGN United States
- Employees
- NAOV N/A
- QLGN N/A
- Industry
- NAOV Industrial Specialties
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- NAOV Health Care
- QLGN Health Care
- Exchange
- NAOV Nasdaq
- QLGN Nasdaq
- Market Cap
- NAOV 2.4M
- QLGN 2.4M
- IPO Year
- NAOV N/A
- QLGN N/A
- Fundamental
- Price
- NAOV $0.38
- QLGN $3.55
- Analyst Decision
- NAOV
- QLGN
- Analyst Count
- NAOV 0
- QLGN 0
- Target Price
- NAOV N/A
- QLGN N/A
- AVG Volume (30 Days)
- NAOV 6.7M
- QLGN 110.9K
- Earning Date
- NAOV 04-07-2025
- QLGN 04-07-2025
- Dividend Yield
- NAOV N/A
- QLGN N/A
- EPS Growth
- NAOV N/A
- QLGN N/A
- EPS
- NAOV N/A
- QLGN N/A
- Revenue
- NAOV $3,291,000.00
- QLGN N/A
- Revenue This Year
- NAOV N/A
- QLGN N/A
- Revenue Next Year
- NAOV N/A
- QLGN N/A
- P/E Ratio
- NAOV N/A
- QLGN N/A
- Revenue Growth
- NAOV 227.79
- QLGN N/A
- 52 Week Low
- NAOV $0.36
- QLGN $2.96
- 52 Week High
- NAOV $1.27
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- NAOV 39.60
- QLGN 47.06
- Support Level
- NAOV $0.36
- QLGN $3.16
- Resistance Level
- NAOV $0.71
- QLGN $3.75
- Average True Range (ATR)
- NAOV 0.06
- QLGN 0.21
- MACD
- NAOV -0.00
- QLGN 0.06
- Stochastic Oscillator
- NAOV 6.19
- QLGN 67.25
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.